Research programme: cancer vaccines - Sapvax

Drug Profile

Research programme: cancer vaccines - Sapvax

Alternative Names: SV-283; SV-638

Latest Information Update: 08 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Auckland
  • Class Cancer vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Malignant melanoma; Non-small cell lung cancer; Ovarian cancer
  • Research Lymphoma; Nasopharyngeal cancer

Most Recent Events

  • 07 Jul 2015 Sapvax plans a phase I trial for SV 283 for Cancer in New Zealand
  • 06 Jul 2015 Early research in Lymphoma and Nasopharyngeal cancer in New Zealand (unspecified route)
  • 06 Jul 2015 Preclinical trials in Non-small cell lung cancer, Ovarian cancer and Malignant melanoma in New Zealand (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top